In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel
In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM). This study concluded that this treatment improves HR-QoL for these patients. Some...
Read MoreEffects of combined treatment with selinexor, carfilzomib and dexamethasone once a week in patients with relapsed/refractory multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...
Read MoreAdding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer
In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...
Read MoreHow safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?
In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...
Read MoreCombining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma
In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL). This study concluded that this treatment combination was safe and effective in these patients. Some background HL is a common cancer...
Read MoreWhich type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?
In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...
Read MoreEvaluating CAR-T cell therapies for treating blood cancers
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This...
Read MoreEvaluating teclistamab for patients with recurrent or unresponsive multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of teclistamab (JNJ-64007957) for patients with recurrent or unresponsive multiple myeloma (MM). This study concluded that this treatment was safe and showed promising effectiveness for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can...
Read MoreEffects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.
In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...
Read MoreEvaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.
In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...
Read MoreIs surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?
In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...
Read More